Influenza vaccine as a coronary intervention for prevention of myocardial infarction

Heart

Volumn 102, Issue 24, 2016, Pages 1953-1956

  MacIntyre, C Raina ^a,b   Mahimbo, Abela ^a   Moa, Aye M ^a   Barnes, Michelle ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; CARDIOVASCULAR MORTALITY; CLINICAL EFFECTIVENESS; CROSS REACTION; CYTOKINE RELEASE; HUMAN; MORBIDITY; NONHUMAN; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SMOKING CESSATION; VACCINATION; ADVERSE EFFECTS; ANIMAL; COMPLICATION; DYSLIPIDEMIAS; HYPERTENSION; INFLUENZA, HUMAN; MYOCARDIAL INFARCTION; PREVENTION AND CONTROL; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SMOKING; TREATMENT OUTCOME; VIROLOGY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; INFLUENZA VACCINES; INFLUENZA, HUMAN; MYOCARDIAL INFARCTION; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME; VACCINATION;

EID: 84990237803     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2016-309983     Document Type: Review

References (49)

1. World Health Organization (WHO). Cardiovascular diseases (CVDs). http://www. who.int/mediacentre/factsheets/fs317/en/ (accessed 4 Apr 2016
2. Kannel WB. Hypertension, blood lipids, and cigarette smoking as co-risk factors for coronary heart disease. Ann N Y Acad Sci 1978; 304: 128-39
3. World Health Organization (WHO). Global status report on noncommunicable diseases 2010. Description of the global burden of NCDs, their risk factors and determinants. 2011. http://www.who.int/nmh/publications/ncd-report-chapter1.pdf?ua=1 (accessed Jan 2015
4. Chow CK, Jolly S, Rao-Melacini P, et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010; 121: 750-8
5. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis 2009; 9: 601-10
6. Collins SD. Excess mortality from causes other than influenza and pneumonia during influenza epidemics. Public Health Reports (1896-1970) 1932; 47: 2159-79
7. Madjid M, Miller CC, Zarubaev VV, et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34, 892 subjects. Eur Heart J 2007; 28: 1205-10
8. Yap FH, Ho PL, Lam KF, et al. Excess hospital admissions for pneumonia, chronic obstructive pulmonary disease, and heart failure during influenza seasons in Hong Kong. J Med Virol 2004; 73: 617-23
9. MacIntyre CR, Heywood AE, Kovoor P, et al. Ischaemic heart disease, influenza and influenza vaccination: a prospective case control study. Heart 2013; 99: 1843-8
10. Clayton T, Capps NE, Stephens NG, et al. Recent respiratory infection and the risk of myocardial infarction. Heart 2005; 91: 1601-2
11. Guan X, Yang W, Sun X, et al. Association of influenza virus infection and inflammatory cytokines with acute myocardial infarction. Inflammation Res 2012; 61: 591-8
12. Meier CR, Jick SS, Derby LE, et al. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet 1998; 351: 1467-71
13. Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with community-Acquired pneumonia: a systematic review and meta-Analysis of observational studies. PLoS Med 2011; 8: e1001048
14. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis 2010; 10: 83-92
15. Fislova T, Gocnik M, Sladkova T, et al. Multiorgan distribution of human influenza A virus strains observed in a mouse model. Arch Virol 2009; 154: 409-19
16. Hsu SY, Chen FL, Liaw YP, et al. A matched influenza vaccine strain was effective in reducing the risk of acute myocardial infarction in elderly persons: a population-based study. Medicine (Baltimore) 2016; 95: e2869
17. Siriwardena AN, Gwini SM, Coupland CAC. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study. CMAJ 2010; 182: 1617-23
18. Barnes M, Heywood AE, Mahimbo A, et al. Acute myocardial infarction and influenza: a meta-Analysis of case-control studies. Heart 2015; 101: 1738-47
19. Ciszewski A, Bilinska ZT, Brydak LB, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J 2008; 29: 1350-8
20. Gurfinkel EP, Leon de la Fuente R, Mendiz O, et al. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. Eur Heart J 2004; 25: 25-31
21. Phrommintikul A, Kuanprasert S, Wongcharoen W, et al. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J 2011; 32: 1730-5
22. Veljkovic V, Glisic S, Veljkovic N, et al. Influenza vaccine as prevention for cardiovascular diseases: possible molecular mechanism. Vaccine 2014; 32: 6569-75
23. Shah AM, Pfeffer MA, Hartley LH, et al. Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction. Am J Cardiol 2010; 106: 911-16
24. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2003; (4): CD003041
25. World Health Organization (WHO). Prevention of Cardiovascular Disease Guidelines for assessment and management of cardiovascular risk. 2007. http://www.who.int/cardiovascular-diseases/guidelines/Full%20text.pdf (accessed Jan 2016
26. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-77
27. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173-8
28. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53
29. Ferrari R, Bertrand ME, Remme WJ, et al. Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial. Expert Rev Cardiovasc Ther 2007; 5: 1037-46
30. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-71
31. Pepine CJ, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: an overview of randomized trials. Clin Cardiol 1998; 21: 633-41
32. Saha SA, Molnar J, Arora RR. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-Analysis of randomized placebo-controlled trials. J Cardiovasc Pharmacol Ther 2007; 12: 192-204
33. Held PH, Yusuf S. Effects of β-blockers and calcium channel blockers in acute myocardial infarction. Eur Heart J 1993; 14(Suppl F): 18-25
34. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991; 67: 1295-7
35. Tonkin A, Aylward P, Colquhoun D, et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57
36. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
37. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9
38. Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-Analysis. J Am Coll Cardiol 2008; 51: 37-45
39. Baigent C, Blackwell L, Emberson J, et al., Cholesterol Treatment Trialists? (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-Analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81
40. Sheng X, Wei L, Murphy MJ, et al. Statins and total (not LDL) cholesterol concentration and outcome of myocardial infarction: results from a meta-Analysis and an observational study. Eur J Clin Pharmacol 2009; 65: 1071-80
41. Gould AL, Davies GM, Alemao E, et al. Cholesterol reduction yields clinical benefits: meta-Analysis including recent trials. Clin Ther 2007; 29: 778-94
42. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-Analysis of randomized controlled trials. JAMA 1999; 282: 2340-6
43. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-Analysis of randomized trials. CMAJ 2008; 178: 576-84
44. Madjid M, Alfred A, Sahai A, et al. Factors contributing to suboptimal vaccination against influenza: results of a nationwide telephone survey of persons with cardiovascular disease. Tex Heart Inst J 2009; 36: 546
45. Ladapo JA, Jaffer FA, Weinstein MC, et al. Projected cost-effectiveness of smoking cessation interventions in patients hospitalized with myocardial infarction. Arch Intern Med 2011; 171: 39-45
46. Tonkin AM, Eckermann S, White H, et al. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study. Am Heart J 2006; 151: 1305-12
47. Newall AT, Scuffham PA, Kelly H, et al. The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia. Vaccine 2008; 26: 2142-53
48. MacIntyre RC, Heywood AE, Kovoor P. Influenza virus vaccine reduces risk of ischemic events: time for a large-scale randomized trial? Future Cardiol 2014; 10: 35-7
49. AIHW. Australian Institute of Health and Welfare 2011. 2009 Adult Vaccination Survey: summary results. Cat. no. PHE 135. Canberra. http://www.aihw.gov.au/publication-detail/?id=10737418409 (accessed Apr 2016